Ever Supreme is optimistic that cell therapy will bring major breakthroughs in medical technology. In recent years, our company has been actively deploying cell new drug research and development. In the future, we hope to lead Taiwan's cell therapy industry into the global market. With optimism on the development of the industry, Ever Supreme is officially registered for pre-OTC on the 26th, and held a pre-OTC conference on the 25th. Many investors were participated with enthusiasm.
Speaking of new drug development, Ever Supreme pointed out that dendritic cell vaccine (ADCV) treatment of malignant brain tumors has approved with orphan drug destination, and is now applying for TFDA Phase II clinical trials. If passed, it is expected to start a clinical trials early next year. As for the stem cells, stem cell drugs for treating myocardial infarction passed the FDA IND application in February this year, and by the TFDA in September this year. Another application on stem cell drugs for treating stroke by intravenous injection was also passed by the FDA for Phase I clinical application in September.
Ever Supreme, with a capital of 560 million New Taiwan Dollars, pointed out that it has signed memorandum of understanding with more than 10 medical facilities and will join with those facilities to enter the cell therapy market in the future. The company will use dendritic cells to treat malignant brain tumors, pancreatic cancer, breast cancer, Lung cancer, colorectal cancer, and ovarian cancer, and current select those indications in the priority list for application. Once it is approved, the company can be put into operation after the inspection. It is expected to bring stable cash flow to the company next year.
Ever Supreme stated that the cell preparation unit in Central Taichung Science Park has been completed and will be used as a base for immune cell production. By combining front-end R&D and back-end clinical trials, and the company will take the lead in the preparation of new cell drugs. In the future, if the "Statue on Regenerative Medicine Preparations" is passed, Ever Supreme is expected to achieve a 5-year interim approval for the new drug license, the Ever Supreme will be able to take its technologies in treating malignant brain tumors, stem cell treatment of myocardial infarction, and stem cell treatment of stroke by dendritic cells. The drug approval will benefit critically ill patients, and for international licensing in the future.
